Gilead Exercises its Option to License Nurix’s NX-0479 for Cancer
Shots:
- Nurix will receive $20M in option exercise fees and receive an additional ~$425M in clinical, regulatory, and commercial milestones along with royalties on product net sales
- Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX‑0479. Gilead signed an agreement with Nurix in June 2019 to discover, develop and commercialize a pipeline of ~5 innovative targeted protein degradation therapies for cancer and other challenging diseases
- Nurix received $45M up front and ~$2.3B in milestones along with royalties on net sales & retain an option to co-develop and co-detail ~2 programs in the US
Ref: Gilead | Image: Gilead
Related News:- Nurix Therapeutics Receives the US FDA’s IND Clearance for NX-1607 to Treat Advanced Malignancies
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
